All In Biotech

Drug Trial Radar · NCT05199584

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

May 24, 2022

Primary completion

Feb 20, 2024

Study completion Feb 20, 2024

Sponsor

Lead sponsor
Endeavor Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.

Conditions

  • Solid Tumors With PTCH1 Loss-of-function Mutations

Interventions

  • ENV-101 (taladegib)Drug

    tablets dosed once-daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: through study completion, an average of 6 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Tampa, Florida

  • Research Site

    Zion, Illinois

  • Research Site

    Covington, Louisiana

  • Research Site

    Las Vegas, Nevada

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Fredericksburg, Virginia

  • Research Site

    Lynchburg, Virginia

  • Research Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.